Last reviewed · How we verify
Caffeine Anhydrous with large sucrose pill
Caffeine Anhydrous with large sucrose pill, developed by the University of Colorado, Denver, is a marketed product with a key composition patent expiring in 2028. The drug's competitive advantage lies in its unique formulation, which may offer improved patient compliance and efficacy. The primary risk is the lack of clear revenue data and key trial results, which could impact investor confidence and market adoption.
At a glance
| Generic name | Caffeine Anhydrous with large sucrose pill |
|---|---|
| Also known as | pure caffeine powder |
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: